Almac Diagnostics Sees Benefit for Test Pipeline in New Ovarian, Breast Cancer Studies
June 07, 2011
Almac Diagnostics Sees Benefit for Test Pipeline in New Ovarian, Breast Cancer Studies
Almac researchers and academic collaborators used the company's Disease Specific Array platform to identify biomarkers associated with ovarian and breast cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Almac Dx Plans to Debut Array-based Colorectal Cancer-Recurrence Test Next Year
November 15, 2011 / BioArray News - After Decade as CRO, Shanghai Biochip Plans Move into Chinese Molecular Dx Market
December 18, 2012 / BioArray News - Team Uses Affy's OncoScan to Develop Prostate Cancer Prognostic Signature, Envisions Clinical Use
October 23, 2012 / BioArray News - Skyline Diagnostics Preps Leukemia Test for US Launch; Gains CE-IVD Mark
March 15, 2011 / BioArray News - Despite Years of Development, Affymetrix's Dx Partners Slow to Bring Tests to Market
March 15, 2011 / BioArray News